Algok Bio, Inc.
PrivateLast Round
Corporate Funding
Nov 16, 2020
Company Overview
Algok Bio, Inc. is a biopharmaceutical company that specializes in the clinical development of targeted oncology therapies for unmet medical needs.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
oncology therapeuticsbiotechnologyprecision medicinedrug developmentclinical trialsbiopharmadrug discoverysmall-molecule drugsmonoclonal antibodytargeted therapybiotech startuplicensing agreementsolid tumorswomen's health
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Algok Bio, Inc. Comparables
Compare Algok Bio, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Epsilogen | 77% | |
| Coherent Biopharma | 76% | |
| Sutro Biopharma Inc | 74% | |
Algok Bio, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Corporate Funding | Nov 16, 2020 |
Algok Bio, Inc. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Algok Bio, Inc.'s valuation, stock price, and market status.
Firmographic Details
HeadquartersBellevue, Washington
Employee Range5
Year Founded2020
Last FundingNov 16, 2020